Story perspectives

CHMP Recommends Five Medicines; Rejects Two Applications

3/28/2026

Summary

Story summary

The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) recommended five medicines for approval in March 2026.
Imdylltra (tarlatamab) for relapsed extensive-stage SCLC showed a 40% reduction in death risk versus standard treatments and a 13.6-month median overall survival.
Zepzelca (lurbinectedin), used with atezolizumab for maintenance in SCLC, demonstrated improved survival outcomes.
CHMP refused to extend marketing authorization for Hetlioz and withdrew an application for Blarcamesine.

1 of 1

Story summary

The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) recommended five medicines for approval in March 2026.
Imdylltra (tarlatamab) for relapsed extensive-stage SCLC showed a 40% reduction in death risk versus standard treatments and a 13.6-month median overall survival.
Zepzelca (lurbinectedin), used with atezolizumab for maintenance in SCLC, demonstrated improved survival outcomes.
CHMP refused to extend marketing authorization for Hetlioz and withdrew an application for Blarcamesine.